These include compounds targeting the mitochondrial DUB USP30 for kidney disease and PD to elevate mitochondrial quality control, yet how the specific inhibition of USP30 can be facilitated on the molecular level had remained elusive. This evidence concerns the gene ZUP1 and Parkinson disease.